Department of Hematology and Oncology, Saarland University Medical School, Homburg, Germany.
Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.
Eur J Haematol. 2021 Jan;106(1):100-104. doi: 10.1111/ejh.13526. Epub 2020 Oct 22.
Previous published data showed an impact of single-nucleotide polymorphisms in the VEGF A and VEGFR2 genes on the survival of patients with various malignancies, among others diffuse large B-cell lymphoma (DLBCL).
We investigated the role of four VEGF-A and two VEGFR-2 gene polymorphisms on the outcome of 273 patients with diffuse large B-cell lymphoma who were treated with R-CHOP within a prospective, randomized trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). The genomic DNA samples were analyzed using commercial DNA Probes (Applied Biosystems, USA) to detect single-nucleotide polymorphisms in the VEGF A rs699947, rs1570360, rs2010963, rs3025039 and rs1870377, and rs2305948 in the VEGFR2 receptor. Hundred healthy blood donors served as a control.
There was no difference between the SNP allele frequencies in lymphoma patients compared to the control group for all investigated SNPs. None of the investigated SNPs was significantly associated with EFS or OS. After adjusting for the International Prognostic Index risk factors in a multivariate analysis, these results could be confirmed.
Single-nucleotide polymorphisms of the VEGF and VEGFR2 were not associated with a worse outcome in Caucasian patients with DLBCL.
之前发表的数据表明，血管内皮生长因子 A (VEGF A) 和血管内皮生长因子受体 2 (VEGFR2) 基因中的单核苷酸多态性对包括弥漫性大 B 细胞淋巴瘤 (DLBCL) 在内的各种恶性肿瘤患者的生存有影响。
我们研究了四个 VEGF-A 和两个 VEGFR-2 基因多态性在 273 例接受 R-CHOP 治疗的弥漫性大 B 细胞淋巴瘤患者结局中的作用，这些患者是德国高级非霍奇金淋巴瘤研究组 (DSHNHL) 的一项前瞻性、随机试验中的一部分。使用商业 DNA 探针（美国应用生物系统公司）分析基因组 DNA 样本，以检测 VEGF A rs699947、rs1570360、rs2010963、rs3025039 和 rs1870377 以及 VEGFR2 受体中的 rs2305948 单核苷酸多态性。100 名健康献血者作为对照组。
与对照组相比，在所有研究的 SNP 中，淋巴瘤患者的 SNP 等位基因频率没有差异。在所研究的 SNP 中，没有一个与 EFS 或 OS 显著相关。在多变量分析中调整国际预后指数危险因素后，可证实这些结果。
在白种人 DLBCL 患者中，VEGF 和 VEGFR2 的单核苷酸多态性与预后不良无关。
